非小细胞肺癌中肝素酶基因与血管内皮生长因子表达的研究

Heparanase and vascular endothelial growth factor expression in non-small-cell lung cancer

目的 探讨肝素酶基因及血管内皮生长因子 (VEGF)在非小细胞肺癌 (NSCLC)中的表达及其临床病理学意义。方法 选取 85例肺部手术标本 ,所有标本分成两份 ,1份用于逆转录PCR检测肝素酶mRNA ,1份用于免疫组化检测VEGF。结果 (1)肝素酶mRNA及VEGF在NSCLC中表达率均高于良性病变肺组织 (P <0 0 5 )。 (2 )肝素酶mRNA表达率在淋巴结转移组、远处转移组、Ⅲ期 +Ⅳ期组、低分化组、腺癌组、肿瘤最大径≥ 5cm组分别高于无淋巴结转移组、无远处转移组、Ⅰ期 +Ⅱ期组、高中分化组、鳞癌组、最大径 <5cm组 (P <0 0 5 )。 (3)VEGF表达率在淋巴结转移组、远处转移组、Ⅲ期 +Ⅳ期组分别高于无淋巴结转移组、无远处转移组、Ⅰ期 +Ⅱ期组 (P <0 0 5 )。 (4 )NSCLC中肝素酶mRNA与VEGF表达无相关性 (P >0 0 5 )。结论 肝素酶与VEGF参与了NSCLC的侵袭转移过程 ,可作为判断NSCLC转移潜力指标 ;肝素酶与VEGF通过互不依赖的机制促进NSCLC的侵袭与转移 ,二者联合检测将有利于提高判断NSCLC转移潜力的敏感性及特异性。

Objective To study the clinicopathological significance of heparanase and VEGF expression in NSCLC. Methods Eighty-five lung samples were studied. Each sample was divided into two parts, one used for heparanase mRNA detection by reverse transcription PCR and the other for VEGF detection by immunohistochemistry. Results (1) The expressions of heparanase mRNA and VEGF were higher in NSCLC than in benign pulmonary diseases ( P <0.05). (2) The expression of heparanase mRNA was higher in cases with lymph-node invasion,metastasis,stageⅢ and Ⅳ diseases, low-differentiation, and adenocarcinoma, as compared to cases without lymph-node invasion and metastasis, with stageⅠandⅡdiseases, higher and moderate differentiation, and squamous cell cancer ( P <0.05). Its expression was higher in tumors larger than 5 cm in size ( P <0.05). (3) The expression of VEGF was higher in cases with lymph-node invasion, metastasis, and stage Ⅲ and Ⅳ disease, as compared to cases without lymph-node invasion and metastasis, and with stageⅠandⅡdiseases ( P <0.05). (4) There was no significant correlation between heparanase and VEGF expression ( P >0.05). Conclusions Heparanase and VEGF are associated with NSCLC invasion and metastasis, and may be used to evaluate NSCLC metastasis status. Heparanase and VEGF promote NSCLC invasion and metastasis by independent mechanisms. Detection of these two markers may improve the sensitivity and specificity of the measurement of NSCLC metastatic potential.